ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Louisville, KY

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Endometrial Cancer
Squamous Cell Carcinoma

Triple Negative Breast Cancer trials near Louisville, KY, USA:

Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3)

selective inhibition of phosphoinositide-3-kinase (PI3K)-gamma, in combinations with Tecentriq and Abraxane (nab-paclitaxel) in front-line triple...

Active, not recruiting
Breast Cancer
Renal Cell Carcinoma
Drug: nab-paclitaxel
Drug: Bevacizumab

Phase 2

Infinity Pharmaceuticals
Infinity Pharmaceuticals

Louisville, Kentucky, United States and 23 other locations

doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC). Usually, after neoadjuvant therapy and surgery for triple ne ...

Active, not recruiting
Triple Negative Breast Cancer
Drug: Placebo
Drug: Atezolizumab

Phase 3

National Surgical Adjuvant Breast and Bowel Project Foundation (NSABP)

Louisville, Kentucky, United States and 216 other locations

or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after su...

Enrolling
Triple Negative Breast Cancer
Drug: Capecitabine
Drug: Sacituzumab govitecan-hziy (SG)

Phase 3

Gilead Sciences
Gilead Sciences

Louisville, Kentucky, United States and 144 other locations

previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do no...

Enrolling
Triple Negative Breast Cancer
PD-L1 Negative
Drug: Sacituzumab Govitecan-hziy
Drug: Paclitaxel

Phase 3

Gilead Sciences
Gilead Sciences

Louisville, Kentucky, United States and 508 other locations

with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors ...

Enrolling
Triple Negative Breast Cancer
PD-L1 Positive
Drug: Pembrolizumab
Drug: Carboplatin

Phase 3

Gilead Sciences
Gilead Sciences

Louisville, Kentucky, United States and 508 other locations

This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC...

Active, not recruiting
Breast Cancer
Drug: Paclitaxel
Drug: Eribulin mesylate

Phase 3

AstraZeneca
AstraZeneca

Louisville, Kentucky, United States and 228 other locations

Locations recently updated

with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvan...

Enrolling
Breast Cancer
Drug: Pembrolizumab
Drug: Dato-DXd

Phase 3

AstraZeneca
AstraZeneca

Louisville, Kentucky, United States and 359 other locations

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without du...

Enrolling
Breast Cancer
Drug: Paclitaxel
Drug: Dato-DXd

Phase 3

AstraZeneca
AstraZeneca

Louisville, Kentucky, United States and 279 other locations

monotherapy versus olaparib in combination with an inhibitor of WEE1 (adavosertib \[AZD1775\]) in second or third line setting in patients with Triple...

Active, not recruiting
Metastatic Triple Negative Breast Cancer
Drug: Olaparib Continuous (28-Day cycle) 300 mg BD.
Drug: Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).

Phase 2

AstraZeneca
AstraZeneca

Louisville, Kentucky, United States and 140 other locations

preliminary antitumor activity of NKT3447 in adult subjects with cyclin E1 (CCNE1) amplified ovarian cancer at the RDEs selected in Dose Es...

Enrolling
Triple Negative Breast Neoplasms
Platinum-resistant Ovarian Cancer
Drug: NKT3447

Phase 1

NiKang Therapeutics

Louisville, Kentucky, United States and 6 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems